Comparison of intravesical adjuvant therapy in bladder cancer with two different maintenance regimens of mitomycin and BCG.

Two year recurrences reduced with use of intravesical Mitomycin during maintenance in the combination group which though not statistically significant favours the trial with combination therapy in future studies. Side effect profile did not worsen with combination of Mitomycin and BCG.